Focus on lymphomas.
Staudt
Louis M
LM
Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. lstaudt@mail.nih.gov
Wilson
Wyndham H
WH
D000074323:Alemtuzumab; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002869:Chromosome Aberrations; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D015870:Gene Expression; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use; D008223:Lymphoma / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D011241:Prednisone / Q000627:therapeutic use; D012307:Risk Factors; D000069283:Rituximab; D013534:Survival; D014612:Vaccines / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D007376:Interleukin-2; D014612:Vaccines; D000074323:Alemtuzumab; D000069283:Rituximab; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone